Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
Melinda L TelliJennifer K LittonJ Thaddeus BeckJason M JonesJay AndersenLida A MinaRaymond BrigMichael DansoYuan YuanWilliam F SymmansJulia F HopkinsLee A AlbackerAntonello AbbattistaKay NoonanMarielena MataA Douglas LairdJoanne L BlumPublished in: Breast cancer (Tokyo, Japan) (2024)
The results from this exploratory biomarker analysis support the central role of BRCA and TP53 mutations in tumor pathobiology. Furthermore, these data support assessing germline BRCA mutational status for molecular eligibility for talazoparib in patients with TNBC.